Equities research analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will report $160,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the highest sales estimate coming in at $230,000.00 and the lowest estimate coming in at $30,000.00. Ascendis Pharma A/S posted sales of $490,000.00 in the same quarter last year, which suggests a negative year-over-year growth rate of 67.3%. The business is expected to issue its next quarterly earnings results on Friday, August 17th.
On average, analysts expect that Ascendis Pharma A/S will report full-year sales of $1.39 million for the current fiscal year, with estimates ranging from $130,000.00 to $4.00 million. For the next year, analysts anticipate that the firm will post sales of $53.24 million per share, with estimates ranging from $130,000.00 to $159.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, May 30th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.38). Ascendis Pharma A/S had a negative return on equity of 64.87% and a negative net margin of 12,089.94%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.30 million.
Ascendis Pharma A/S opened at $66.82 on Friday, according to MarketBeat. Ascendis Pharma A/S has a 1 year low of $26.30 and a 1 year high of $76.29. The firm has a market cap of $2.83 billion, a price-to-earnings ratio of -15.43 and a beta of 0.67.
Several institutional investors and hedge funds have recently modified their holdings of ASND. Wells Fargo & Company MN raised its position in shares of Ascendis Pharma A/S by 41.5% in the fourth quarter. Wells Fargo & Company MN now owns 42,556 shares of the biotechnology company’s stock valued at $1,705,000 after purchasing an additional 12,480 shares during the period. BlackRock Inc. bought a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at about $17,279,000. Alliancebernstein L.P. raised its position in shares of Ascendis Pharma A/S by 85.1% in the fourth quarter. Alliancebernstein L.P. now owns 55,540 shares of the biotechnology company’s stock valued at $2,225,000 after purchasing an additional 25,540 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at about $650,000. Finally, Alps Advisors Inc. raised its position in shares of Ascendis Pharma A/S by 21.0% in the first quarter. Alps Advisors Inc. now owns 48,775 shares of the biotechnology company’s stock valued at $3,190,000 after purchasing an additional 8,478 shares during the period. 91.83% of the stock is currently owned by institutional investors.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Story: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.